Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

Journal of Neuroscience

Volumn 21, Issue 17, 2001, Pages 6853-6861

  Bezard, Erwan ^a,b   Dovero, Sandra ^b   Prunier, Caroline ^c   Ravenscroft, Paula ^a   Chalon, Sylvie ^c   Guilloteau, Denis ^c   Crossman, Alan R ^a,d   Bioulac, Bernard ^b   Brotchie, Jonathan M ^a,d   Gross, Christian E ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d Williams House   (United Kingdom)

Author keywords

Compensatory mechanisms; Dopaminergic homeostasis; Early D2 dopaminergic receptor upregulation; Striatum; Substantia nigra; Threshold for symptom appearance

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENERVATION; DISEASE ASSOCIATION; DOPAMINE METABOLISM; HOMEOSTASIS; IN VIVO STUDY; NONHUMAN; PARKINSON DISEASE; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION; REGULATORY MECHANISM; STRIATONIGRAL DEGENERATION;

EID: 0035449393     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.21-17-06853.2001     Document Type: Article

References (69)

1. Estimation of nuclear population from microtome sections
2. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations
3. Compensatory mechanisms in experimental and human Parkinsonism: Towards a dynamic approach
4. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental Parkinsonism
5. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: Evolution of motor symptoms in the monkey
6. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms
7. Evolution of the multiunit activity of basal ganglia in the course of a dynamic experimental Parkinsonism
8. Pallidal border cells: An anatomical and electrophysiological study in the MPTP-treated monkey
9. Structures outside the basal ganglia may compensate for dopamine loss in the pre-symptomatic stages of Parkinson's disease
10. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of Parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
11. 3H-spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
12. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
13. 1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions
14. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease
15. Dopamine receptor binding: Enhancement accompanying lesion-induced behavioural supersensitivity
16. The substantia nigra of the human brain - I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D-28K immunohisto-chemistry
17. The substantia nigra of the human brain - II. Patterns of loss of dopamine-containing neurons in Parkinson's disease
18. Differential regulation of striatal dopamine D-1 and D-2 receptors in acute and chronic Parkinsonian monkeys
19. Alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex
20. Primate models of movement disorders of basal ganglia origin
21. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys
22. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems
23. Striatal dopaminergic correlates of stable Parkinsonism and degree of recovery in Old-World primates one year after MPTP treatment
24. Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carboxymethoxy-3β-(4′-iodophenyl) nortropane and N-(3-iodoprop-2E-enyl)- 2β-carboxymethoxy-3β-(3′,4′-disubstituted phenyl) nortropane: New high-affinity and selective compounds for the dopamine transporter
25. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys
26. Ageing and Parkinson's disease: Substantia nigra regional selectivity
27. Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter
28. Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals
29. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost?
30. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9, and A10 dopaminergic neurons in the mouse
31. Autoradiographic studies in animal models of hemi-Parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra- carotid infusion of MPTP in the monkey (Macaca fascicularis)
32. Exploration of the dopamine transporter: In vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2b-carbomethoxy-3b-(4′-methylphenyl) nortropane (PE2I)
33. Zur Pathologie der Paralysis Agitans und des posten-zephalitischen Parkinsonismus
34. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
35. Mechanism and consequences of nerve cell death in Parkinson's disease
36. Melanized dopaminergic neurons are differentially affected in Parkinson's disease
37. Parkinsonism: Onset, progression and mortality
38. Biochemical pathophysiology of Parkinson's disease
39. Comparison between eight clinical rating scales used for the assessment of MPTP-induced Parkinsonism in the macaque monkey
40. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey
41. Dopamine receptors and brain function
42. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications
43. Does a long preclinical period occur in Parkinson's disease?
44. Receptor basis for dopaminergic supersensitivity in Parkinson's disease
45. 2 dopamine receptors in brain with subtype-specific antibodies
46. 1 binding density following mesotelencephalic 6-hydroxydopamine injections: An autoradiographic analysis
47. Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fast-scan in vivo voltammetry
48. Rate of cell death in Parkinsonism indicates active neuropathological process
49. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine
50. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D-1 or D-2 receptor agonists
51. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease
52. MPTP-induced Parkinsonism in primates: Pattern of striatal dopamine loss following acute and chronic administration
53. Time course of nigrostriatal degeneration in Parkinson's disease
54. Striatal preproenkephalin gene expression is upregulated in acute but not chronic Parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to Parkinsonian symptomatology
55. Pattern of dopaminergic loss in the striatum of humans with MPTP induced Parkinsonism
56. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: Evidence for compensatory hyperactivity of residual terminals
57. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage
58. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents
59. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)
60. Behavioral effects of MPTP administration in the Vervet monkey, a primate model of Parkinson's disease
61. Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice
62. 3 receptor protein and mRNA in response to 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons
63. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons
64. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism
65. A dopamine-and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions
66. Animal models of Parkinsonism using selective neurotoxins: Clinical and basic implications
67. Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications
68. Wiring and volume transmission in the central nervous system: The concept of closed and open synapses